Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

Discover why Tempus AI Inc (NASDAQ:TEM) stock is surging today following major platform expansions and landmark clinical data ahead of ASCO 2026.

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio